Shares of Immune Pharmaceuticals Inc (NASDAQ:IMNP) have been given a consensus broker rating score of 3.00 (Hold) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating. Immune Pharmaceuticals’ rating score has declined by 200% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.

Zacks has also given Immune Pharmaceuticals an industry rank of 82 out of 255 based on the ratings given to its competitors.

Separately, Maxim Group downgraded shares of Immune Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 6th.

Shares of Immune Pharmaceuticals stock remained flat at $$0.05 on Monday. 264,329 shares of the stock were exchanged, compared to its average volume of 900,677. The company has a current ratio of 0.31, a quick ratio of 0.31 and a debt-to-equity ratio of 0.15. Immune Pharmaceuticals has a 52-week low of $0.04 and a 52-week high of $1.05.

Immune Pharmaceuticals (NASDAQ:IMNP) last issued its quarterly earnings data on Tuesday, August 14th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter.

About Immune Pharmaceuticals

Immune Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis.

Recommended Story: Does the discount rate affect the economy?

Get a free copy of the Zacks research report on Immune Pharmaceuticals (IMNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.